AB5200
Anti-Potassium Channel GIRK2 Antibody
Chemicon®, from rabbit
Synonyme(s) :
G-protein Activated Inwardly Rectifying Potassium Channel
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
eCl@ss :
32160702
Nomenclature NACRES :
NA.41
Produits recommandés
Source biologique
rabbit
Niveau de qualité
Forme d'anticorps
affinity purified immunoglobulin
Type de produit anticorps
primary antibodies
Clone
polyclonal
Produit purifié par
affinity chromatography
Espèces réactives
mouse, rat
Fabricant/nom de marque
Chemicon®
Technique(s)
immunohistochemistry: suitable
western blot: suitable
Numéro d'accès NCBI
Numéro d'accès UniProt
Conditions d'expédition
wet ice
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
human ... KCNJ6(3763)
Catégories apparentées
Spécificité
Recognizes a full length Kir3.2 (GIRK2, G-protein Activated Inwardly Rectifying Potassium Channel 2). Does not cross react with any other potassium channel antigens tested so far.
Immunogène
GST fusion protein from the C-terminal portion of mouse GIRK2 protein (amino acids 374-414) (Accession P48542).
Application
Anti-Potassium Channel GIRK2 Antibody detects level of Potassium Channel GIRK2 & has been published & validated for use in IH & WB.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Ion Channels & Transporters
Ion Channels & Transporters
Western blot: 1:200 using ECL on rat brain membranes.
Immunohistochemistry on rat brain sections.
Dilutions should be made using a carrier protein such as BSA (1-3%)
Optimal working dilutions must be determined by the end user.
Immunohistochemistry on rat brain sections.
Dilutions should be made using a carrier protein such as BSA (1-3%)
Optimal working dilutions must be determined by the end user.
Forme physique
Affinity purified immunoglobulin. Lyophilized from phosphate buffered saline, pH 7.4, containing 1% BSA, 5% sucrose as a stabilizer and 0.025% sodium azide as a preservative. Reconstitute with 200 μL of sterile deionized water. Centrifuge antibody preparation before use (10,000 xg for 5 min).
Stockage et stabilité
Maintain lyophilized material at -20°C for up to 12 months. After reconstitution maintain at -20°C in undiluted aliquots for up to 6 months. Avoid repeated freeze/thaw cycles
Remarque sur l'analyse
Control
CONTROL ANTIGEN: Included free of charge with the antibody is 120 μg of control antigen (lyophilized powder). The stock solution of the antigen can be made up using 100 μL of PBS. For positive control, in Western blot use 20 ng of protein per minigel lane. For negative control, preincubate 3 μg of fusion protein with 1 μg of antibody for one hour at room temperature. Optimal concentrations must be determined by the end user.
CONTROL ANTIGEN: Included free of charge with the antibody is 120 μg of control antigen (lyophilized powder). The stock solution of the antigen can be made up using 100 μL of PBS. For positive control, in Western blot use 20 ng of protein per minigel lane. For negative control, preincubate 3 μg of fusion protein with 1 μg of antibody for one hour at room temperature. Optimal concentrations must be determined by the end user.
Autres remarques
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Informations légales
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Clause de non-responsabilité
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Mentions de danger
Conseils de prudence
Classification des risques
Aquatic Chronic 3
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Tammy Ryan et al.
Nature communications, 9(1), 817-817 (2018-02-28)
Neuronal loss in Parkinson's disease (PD) is associated with aberrant mitochondrial function and impaired proteostasis. Identifying the mechanisms that link these pathologies is critical to furthering our understanding of PD pathogenesis. Using human pluripotent stem cells (hPSCs) that allow comparison
Andrzej Swistowski et al.
Current protocols in stem cell biology, Chapter 2, Unit2D-Unit2D (2012-08-09)
Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are potentially an unlimited cell source for cell replacement therapy and personalized medicine. Before hESC- and iPSC-based therapy can be moved from bench to bedside, however, it is essential
Andrzej Swistowski et al.
PloS one, 4(7), e6233-e6233 (2009-07-15)
Human embryonic stem cells (hESCs) may provide an invaluable resource for regenerative medicine. To move hESCs towards the clinic it is important that cells with therapeutic potential be reproducibly generated under completely defined conditions. Here we report a four-step scalable
Fahad Mubariz et al.
Frontiers in neuroscience, 17, 1152503-1152503 (2023-06-19)
Mutations in the GBA1 gene are the single most frequent genetic risk factor for Parkinson's disease (PD). Neurodegenerative changes in GBA1-associated PD have been linked to the defective lysosomal clearance of autophagic substrates and aggregate-prone proteins. To elucidate novel mechanisms
Adolfo López-Ornelas et al.
Cells, 12(23) (2023-12-09)
Human embryonic stem cells (hESCs) differentiate into specialized cells, including midbrain dopaminergic neurons (DANs), and Non-human primates (NHPs) injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine develop some alterations observed in Parkinson's disease (PD) patients. Here, we obtained well-characterized DANs from hESCs and transplanted them
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique